Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6%

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Unexpected Gains.

Hims & Hers bounced back by 6.22 percent on Monday to close at $20.33 apiece, as investors positioned their second-quarter portfolios backed by optimism over its rekindled partnership with Novo Nordisk to jointly capitalize on the $200 billion obesity treatment market.

Late last month, Hims & Hers Health Inc. (NYSE:HIMS) announced that Novo Nordisk’s blockbuster drugs, Wegovy and Ozempic, are now back on its platform.

Eligible customers seeking to purchase the said treatments can avail both pill and injectable versions of Wegovy, except for the 7.2 mg injection, which has yet to be launched. Ozempic injectable pens are also available across all dosages.

PROCEPT BioRobotics (PRCT) Strengthens Its Case with Expanding System Base

Nestor Rizhniak/Shutterstock.com

“As the largest global consumer health platform, we’re thrilled to be working alongside Novo Nordisk to help more people feel their best and we’re excited to find more ways to collaborate across the industry,” said Hims & Hers Health Inc. (NYSE:HIMS) CEO Andrew Dudum.

For his part, Hims & Hers Health Inc. (NYSE:HIMS) SVP for Weight Management Craig Primack noted that obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient.

“As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We’re excited to see how our customers succeed as more innovative treatments become available,” he noted.

In a study published in February this year, JPMorgan said that it expects the global incretin market to soar to as much as $200 billion over the next four years, thanks to reduced prices and continued strong demand for weight loss treatments.

It noted that the number of Americans alone adopting the treatment is projected to soar by 150 percent by 2030 to 25 million from 10 million previously.

While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.